Antera Therapeutics Announces First and Only Commercial Product Based on LEAP for Early Peanut Introduction

LOS ANGELES, March 5, 2016 /PRNewswire/ -- Today, at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, Antera Therapeutics (www.anteratherapeutics.com) announced the launch of Aralyte™, a new food for special dietary use regimen that directly incorporates the groundbreaking findings of the LEAP (Learning Early About Peanut Allergy) Clinical Program. Antera's announcement coincides with the LEAP-On Study announced at the AAAAI and published in the New England Journal of Medicine, which demonstrates the on-going persistence of the original allergy reduction shown in LEAP.

The first LEAP Study, presented at last year's AAAAI Annual Meeting, showed more than an 80 percent relative risk reduction of peanut allergy development in infants who were exposed to a consistent regimen of peanut protein. Following publication, ten medical associations, including the AAAAI and the American Academy of Pediatrics (AAP) now recommend early-introduction of peanut protein. With this new approach, medical professionals hope to reverse the alarming trend of increasing peanut allergies, which tripled between 1997 and 2008 in the U.S.

"Many parents and physicians are looking for a safe, standardized approach based on the clinically validated amounts and regimen of the LEAP Study," said Clarence Friedman, President of Antera Therapeutics. "Aralyte provides that comfort by bringing LEAP's clinical protocol and introduction regimen into widespread clinical use, thereby removing the guesswork around early introduction of peanuts."

Aralyte is an all-natural, organic food for special dietary use that offers parents a safe and structured means of implementing the LEAP regimen. The liquid formula contains the precise protein amounts used in the study and contains full doses of vitamins, such as vitamin D, making it perfect for use in combination with breastfeeding or formula. The daily, single-use doses also promote adherence, eliminate mess, and leave kitchenware uncontaminated for increased safety around family members who might already be allergic. The formula is less than a teaspoon of liquid and was designed for both direct feeding or mixing with infants' food.

Additionally, the first dose of Aralyte is administered in the physician's office, which increases safety and reduces parental anxiety about early introduction. After obtaining a prescription, parents then receive the Aralyte regimen and complete the convenient daily dosing in the comfort of their own home.

Antera is now taking pre-orders for Aralyte Start™ and expects national product availability in 2016.

SOURCE Antera Therapeutics

Related Links

http://www.anteratherapeutics.com